By simultaneously targeting SIRT1 and inosine monophosphate dehydrogenase 2, INZ inhibits the development of cancer cells by inducing ribosomal stress, RPL11/RPL5-MDM2 association, activating p53, and blocking SIRT1 277. This evidence concerns the gene TP53 and cancer.